Pharmanutra’s stock has been cooling for weeks, with the share price down about 14% over three months and a rich P/E near 36x that asks investors to pay up for the story. The latest quarter has given that premium a fresh stress test. Revenue reached €41.0m and net income hit €6.5m, solid figures that keep the growth narrative alive but come against a backdrop of a share price already trading above a discounted cash flow estimate of €64.01. The tension between strong reported progress and an expensive valuation is now front and centre.

Is Pharmanutra already pricing in years of strong growth, or has the recent pullback begun to create a margin of safety for new investors? Explore the gap between premium multiples and cash flow…